Pharmacosmos A/S

The global iron deficiency anemia treatment market is projected to grow to US$ 22.7 billion by 2030, driven by increasing prevalence, awareness, and advancements in treatment options. Key players are focusing on product diversification, collaborations, and R&D to cater to the growing demand, especially in emerging markets.

DelveInsight's report on Iron Deficiency Anemia covers epidemiology, market trends in the US, EU4, UK, and Japan. Key trials include Dr. P. Noordzij's study on postoperative iron deficiency anemia treatment and RDC Clinical Pty Ltd's trial on IHAT. The US had 9.5 million prevalent cases in 2023, with females accounting for 65% of cases. Leading companies and therapies are highlighted, including MegaPro Biomedical's MPB-1514 and Pharmacosmos A/S's Ferric Derisomaltose. The report also discusses treatment strategies and market dynamics.

The hemoglobinopathies treatment market is projected to grow from $8.2 billion in 2023 to $13.2 billion by 2028, driven by genetic inheritance, advancements in cell-based gene therapies, and personalized medicine. Key players include Pfizer, Sanofi, and Vertex Pharmaceuticals.

DelveInsight's report on Congestive Heart Failure Market (2020-2034) covers epidemiology, market trends, key companies, and therapies. Market size was ~USD 6,900 million in 2023, expected to grow significantly. Key companies include Novartis, Bayer, and Eli Lilly. Therapies like ENTRESTO and JARDIANCE are highlighted. Market drivers include aging population and disease prevalence, while barriers include generic therapies and diagnostic challenges.